Paul Volberding, MD

Photo of Paul Volberding, MD

Email Paul
(415) 476-5470

550 16th. Street
San Francisco, CA 94158

Visit CTSI Profile
  • Professor, School of Medicine
  • Former Co-Director and Principal Investigator, UCSF-Gladstone CFAR

Biography

I was trained in Medical Oncology but became involved in the early AIDS epidemic in San Francisco based at San Francisco General Hospital. I have worked in clinical trials in HIV-related malignancies but primarily in the development of antiretroviral therapy. I was the PI and co-director with Warner Greene of the NIAID-funded UCSF-Gladstone Center for AIDS Research supporting the large community of HIV investigators in San Francisco. CFAR provides core services, pilot grants to early career stage investigators and supports a comprehensive mentorship program. In the Clinical and Translational Sciences Institute I served as a member of the Board of Directors and formerly directed the Global Health Program. I stepped down as the Chief of the Medical Service at the San Francisco VA Medical Center in 2012 to become the Director of the UCSF AIDS Research Institute. The ARI is the comprehensive University organization that links all HIV/AIDS research programs and is the central focus for communications, media relations and philanthropic support for this internationally recognized response to the HIV epidemic. In 2015, the ARI became the administrative home for a unique initiative to cure HIV infection funded by amfAR, the Foundation for AIDS Research. I served until recently as the Director of the amfAR Institute for HIV Cure, working with leading scientists at UCSF, the Gladstone Institute for Virology and Immunology, and the Vitalant (formerly the Blood Systems) Research Institute. I also served as the Associate Chair of the UCSF Department of Medicine for Global Health. My clinical appointment is at the VA as a retired volunteer physician where I maintain an active HIV outpatient practice. I am the Clinical Editor in Chief of the Journal of the Acquired Immunodeficiency Syndromes and served as the Chair of the Scientific Advisory Board of the Accordia Global AIDS Foundation and the Infectious Diseases Institute at Makerere University in Kampala Uganda. I was a board member of the Pangaea Global AIDS Foundation. I am an active member of the National Academy of Medicine (formerly the Institute of Medicine) of the National Academy of Sciences and am the founder and Board Chair of the International Antiviral Society-USA. On Twitter I am @pvolberding.

Displaying 1 - 240 of 240

  1. Volberding P. Sharing Experiences and Lessons: Medical Issues in Confronting the HIV Epidemic and COVID-19. Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):343-345. View on Pubmed
  2. Harding BN, Whitney BM, Nance RM, Ruderman SA, Crane HM, Burkholder G, Moore RD, Mathews WC, Eron JJ, Hunt PW, Volberding P, Rodriguez B, Mayer KH, Saag MS, Kitahata MM, Heckbert SR, Delaney JAC. Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study. BMC Infect Dis. 2020 Mar 20; 20(1):238. View on Pubmed
  3. Harding BN, Whitney BM, Nance RM, Crane HM, Burkholder G, Moore RD, Mathews WC, Eron JJ, Hunt PW, Volberding P, Rodriguez B, Mayer K, Saag MS, Kitahata MM, Heckbert SR, Delaney JAC. Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. BMJ Open. 2020 03 19; 10(3):e031487. View on Pubmed
  4. Heinemann AW, Volberding PA. National Academies Consensus Report on Functional Assessment for Adults With Disabilities. Arch Phys Med Rehabil. 2019 12; 100(12):2407-2408. View on Pubmed
  5. Volberding P, Chambers HF. Antimicrobial Drug Development Efficiency and Surrogate Markers of Clinical Benefit. JAMA Intern Med. 2019 Nov 11. View on Pubmed
  6. Kang M, Grund B, Hunsberger S, Glidden D, Volberding P. Interim monitoring in a treatment strategy trial with a composite primary endpoint. Contemp Clin Trials. 2019 11; 86:105846. View on Pubmed
  7. Satre DD, Anderson AN, Leibowitz AS, Levine-Hall T, Slome S, Flamm J, Hare CB, McNeely J, Weisner CM, Horberg MA, Volberding P, Silverberg MJ. Implementing electronic substance use disorder and depression and anxiety screening and behavioral interventions in primary care clinics serving people with HIV: Protocol for the Promoting Access to Care Engagement (PACE) trial. Contemp Clin Trials. 2019 09; 84:105833. View on Pubmed
  8. Scott H, Volberding PA. HIV Screening and Preexposure Prophylaxis Guidelines: Following the Evidence. JAMA. 2019 06 11; 321(22):2172-2174. View on Pubmed
  9. Satre DD, Leibowitz AS, Leyden W, Catz SL, Hare CB, Jang H, Lam JO, Bryant KJ, Weisner CM, Sterling SA, Horberg M, Volberding P, Silverberg MJ. Interventions to Reduce Unhealthy Alcohol Use among Primary Care Patients with HIV: the Health and Motivation Randomized Clinical Trial. J Gen Intern Med. 2019 10; 34(10):2054-2061. View on Pubmed
  10. Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infect Dis. 2019 Jan; 6(1):ofy353. View on Pubmed
  11. Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963. View on Pubmed
  12. Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018 08 31; 128(9):4074-4085. View on Pubmed
  13. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 07 24; 320(4):379-396. View on Pubmed
  14. Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, Skiest DJ, Gandhi RT, Kuritzkes DR, O'Doherty U, Li JZ. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. J Virol. 2018 06 15; 92(12). View on Pubmed
  15. Benson CA, Currier JS, Del Rio C, Gallant JE, Gulick RM, Marrazzo JM, Richman DD, Saag MS, Schooley RT, Volberding PA. A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. Top Antivir Med. 2017 Dec/Jan; 24(4):142-151. View on Pubmed
  16. Malekinejad M, Parriott A, Blodgett JC, Horvath H, Shrestha RK, Hutchinson AB, Volberding P, Kahn JG. Effectiveness of community-based condom distribution interventions to prevent HIV in the United States: A systematic review and meta-analysis. PLoS One. 2017; 12(8):e0180718. View on Pubmed
  17. Volberding PA. How to Survive a Plague: The Next Great HIV/AIDS History. JAMA. 2017 04 04; 317(13):1298-1299. View on Pubmed
  18. Volberding PA. HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. Top Antivir Med. 2017 Feb/Mar; 25(1):17-24. View on Pubmed
  19. Volberding P, Blattner WA. JAIDS: Transitions, Evolution, and Impact. J Acquir Immune Defic Syndr. 2017 01 01; 74(1):1-2. View on Pubmed
  20. Satre DD, Altschuler A, Parthasarathy S, Silverberg MJ, Volberding P, Campbell CI. Implementation and Operational Research: Affordable Care Act Implementation in a California Health Care System Leads to Growth in HIV-Positive Patient Enrollment and Changes in Patient Characteristics. J Acquir Immune Defic Syndr. 2016 Dec 15; 73(5):e76-e82. View on Pubmed
  21. Rich ZC, Chu C, Mao J, Zhou K, Cai W, Ma Q, Volberding P, Tucker JD. Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals. BMC Public Health. 2016 09 20; 16:994. View on Pubmed
  22. Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017 01; 19(1):99-108. View on Pubmed
  23. Meffert SM, Shome S, Neylan TC, Musalo K, Fineberg HV, Cooke MM, Volberding PA, Goosby EP. Health impact of human rights testimony: harming the most vulnerable? BMJ Glob Health. 2016; 1(1):e000001. View on Pubmed
  24. Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12; 316(2):191-210. View on Pubmed
  25. Chu CE, Wu F, He X, Zhou K, Cheng Y, Cai W, Geng E, Volberding P, Tucker JD. Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion. Open Forum Infect Dis. 2016 Apr; 3(2):ofw065. View on Pubmed
  26. Tang W, Han L, Best J, Zhang Y, Mollan K, Kim J, Liu F, Hudgens M, Bayus B, Terris-Prestholt F, Galler S, Yang L, Peeling R, Volberding P, Ma B, Xu H, Yang B, Huang S, Fenton K, Wei C, Tucker JD. Crowdsourcing HIV Test Promotion Videos: A Noninferiority Randomized Controlled Trial in China. Clin Infect Dis. 2016 06 01; 62(11):1436-1442. View on Pubmed
  27. Shearer DW, Volberding PA, Schemitsch EH, Cook GE, Slobogean GP, Morshed S. Building Networks for Global Clinical Research: The Basics. J Orthop Trauma. 2015 Dec; 29 Suppl 12:S15-8. View on Pubmed
  28. Chu CE, Wu F, He X, Ma Q, Cheng Y, Cai W, Volberding P, Tucker JD. Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. AIDS Res Hum Retroviruses. 2015 Jan; 31(1):78-84. View on Pubmed
  29. Lambdin BH, Cheng B, Peter T, Mbwambo J, Apollo T, Dunbar M, Udoh IC, Cattamanchi A, Geng EH, Volberding P. Implementing Implementation Science: An Approach for HIV Prevention, Care and Treatment Programs. Curr HIV Res. 2015; 13(3):244-9. View on Pubmed
  30. Volberding PA. Highlights of the 2014 International AIDS Conference: update from down under. Top Antivir Med. 2014 Dec-2015 Jan; 22(5):694-7. View on Pubmed
  31. Tucker JD, Volberding PA, Margolis DM, Rennie S, Barré-Sinoussi F. Words matter: Discussing research towards an HIV cure in research and clinical contexts. J Acquir Immune Defic Syndr. 2014 Nov 01; 67(3):e110-1. View on Pubmed
  32. Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014 Jul 23-30; 312(4):410-25. View on Pubmed
  33. Volberding P. HIV cure: the target is clearer but not yet close. Ann Intern Med. 2014 Apr 01; 160(7):505-6. View on Pubmed
  34. Volberding PA. Solving the mystery of JAIDS. J Acquir Immune Defic Syndr. 2013 Aug 01; 63(4):417. View on Pubmed
  35. Das M, Volberding P. Bringing the end in sight: consensus regarding HIV screening strategies. Ann Intern Med. 2013 Jul 02; 159(1):63-4. View on Pubmed
  36. El-Sadr WM, Morrison JS, Quinn T, Volberding P. A chronicle of hope and promise: the world as it was, as it is, and as it can be. J Acquir Immune Defic Syndr. 2012 Aug 15; 60 Suppl 3:S49-50. View on Pubmed
  37. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012 Jul 25; 308(4):387-402. View on Pubmed
  38. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, Deren S, Effros RB, Gebo K, Goronzy JJ, Justice AC, Landay A, Levin J, Miotti PG, Munk RJ, Nass H, Rinaldo CR, Shlipak MG, Tracy R, Valcour V, Vance DE, Walston JD, Volberding P. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012 Jul 01; 60 Suppl 1:S1-18. View on Pubmed
  39. Volberding P. The impact of HIV research on health outcome and healthcare policy. Ann Oncol. 2011 Nov; 22 Suppl 7:vii50-vii53. View on Pubmed
  40. Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P. Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. J Acquir Immune Defic Syndr. 2011 Sep 01; 58(1):1-8. View on Pubmed
  41. Tabas JA, Boscardin C, Jacobsen DM, Steinman MA, Volberding PA, Baron RB. Clinician attitudes about commercial support of continuing medical education: results of a detailed survey. Arch Intern Med. 2011 May 09; 171(9):840-6. View on Pubmed
  42. Martin J, Volberding P. HIV and premature aging: A field still in its infancy. Ann Intern Med. 2010 Oct 05; 153(7):477-9. View on Pubmed
  43. Dykes C, Mukherjee AL, Bosch RJ, Connick E, Volberding PA, Demeter LM. Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371. J Acquir Immune Defic Syndr. 2010 Sep; 55(1):132-4. View on Pubmed
  44. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010 Jul 21; 304(3):321-33. View on Pubmed
  45. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 03; 376(9734):49-62. View on Pubmed
  46. Choi AI, Li Y, Parikh C, Volberding PA, Shlipak MG. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int. 2010 Sep; 78(5):478-85. View on Pubmed
  47. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010 Feb 09; 121(5):651-8. View on Pubmed
  48. Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, Vogler M, Martinez A, Little S, Connick E. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. 2009 Sep 24; 23(15):1987-95. View on Pubmed
  49. Volberding P. Cohorts, trials, and evidence: expanding our confidence in guidelines for antiretroviral resistance testing. Ann Intern Med. 2009 Jul 21; 151(2):135-6. View on Pubmed
  50. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008 Aug 06; 300(5):555-70. View on Pubmed
  51. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, Bostrom A, O'Hare AM. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis. 2007 Dec 15; 45(12):1633-9. View on Pubmed
  52. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol. 2007 Nov; 18(11):2968-74. View on Pubmed
  53. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. The impact of HIV on chronic kidney disease outcomes. Kidney Int. 2007 Dec; 72(11):1380-7. View on Pubmed
  54. Behler CM, Vittinghoff E, Lin F, Chung RT, Peters MG, Robbins GK, Volberding PA. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis. 2007 May 15; 44(10):1375-83. View on Pubmed
  55. Holodniy M, Hornberger J, Rapoport D, Robertus K, MaCurdy TE, Lopez J, Volberding P, Deyton L. Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004). J Acquir Immune Defic Syndr. 2007 Jan 01; 44(1):20-9. View on Pubmed
  56. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006 Aug 16; 296(7):827-43. View on Pubmed
  57. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006 Aug-Sep; 14(3):827-43. View on Pubmed
  58. Volberding PA. The New York case: lessons being learned. Ann Intern Med. 2005 May 17; 142(10):866-8. View on Pubmed
  59. Behler C, Shade S, Gregory K, Abrams D, Volberding P. Anemia and HIV in the antiretroviral era: potential significance of testosterone. AIDS Res Hum Retroviruses. 2005 Mar; 21(3):200-6. View on Pubmed
  60. Michaels MG, Kaufman C, Volberding PA, Gupta P, Switzer WM, Heneine W, Sandstrom P, Kaplan L, Swift P, Damon L, Ildstad ST. Baboon bone-marrow xenotransplant in a patient with advanced HIV disease: case report and 8-year follow-up. Transplantation. 2004 Dec 15; 78(11):1582-9. View on Pubmed
  61. Henry DH, Volberding PA, Leitz G. Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future. J Acquir Immune Defic Syndr. 2004 Oct 01; 37(2):1221-7. View on Pubmed
  62. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004 Jul 29; 351(5):451-9. View on Pubmed
  63. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004 Jul 14; 292(2):251-65. View on Pubmed
  64. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004 May 15; 38(10):1454-63. View on Pubmed
  65. Volberding PA. Initiating HIV therapy. Timing is critical, controversial. Postgrad Med. 2004 Feb; 115(2):15-8, 21, 24-6. View on Pubmed
  66. Volberding PA. Opportunities and options for treatment research in resource-constrained settings. Clin Infect Dis. 2003 Jul 01; 37(Suppl 1):S1-3. View on Pubmed
  67. Volberding PA. HIV therapy in 2003: consensus and controversy. AIDS. 2003 Apr; 17 Suppl 1:S4-11. View on Pubmed
  68. Volberding PA, Murphy RL, Barbaro G, Barbarini G, Bruno R, Cirelli A, Currie PF, Di Lorenzo G, Fantoni M, Filiced G, Galli M, Grisorio B, Moroni M, Recusani F, Sacchi P, Scevola D, Stein JH, Torre D, Vittecoq D. The pavia consensus statement. AIDS. 2003 Apr; 17 Suppl 1:S170-9. View on Pubmed
  69. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 2003 Mar 28; 17(5):691-8. View on Pubmed
  70. Volberding PA, Baker KR, Levine AM. Human immunodeficiency virus hematology. Hematology Am Soc Hematol Educ Program. 2003; 294-313. View on Pubmed
  71. Blower S, Volberding P. What can modeling tell us about the threat of antiviral drug resistance? Curr Opin Infect Dis. 2002 Dec; 15(6):609-14. View on Pubmed
  72. Volberding P. Adherence, resistance, and timing: current issues in the use of new therapies. AIDS Read. 2002 Aug; 12(8):349-50, 356-7, 368. View on Pubmed
  73. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002 Jul 10; 288(2):222-35. View on Pubmed
  74. Rossi SJ, Volberding PA, Wright TL. Does hepatitis C virus infection increase the risk of HIV disease progression? JAMA. 2002 Jul 10; 288(2):241-3. View on Pubmed
  75. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses. 2002 Jul 01; 18(10):685-93. View on Pubmed
  76. Volberding P, Sullivan P. Introduction: the importance of identifying and treating complications of human immunodeficiency virus disease. J Infect Dis. 2002 May 15; 185 Suppl 2:S103-4. View on Pubmed
  77. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. J Infect Dis. 2002 May 15; 185 Suppl 2:S110-4. View on Pubmed
  78. Volberding PA. Who cares for AIDS? J Gen Intern Med. 2002 Jan; 17(1):82-3. View on Pubmed
  79. Boswell SL, Hecht FM, Powderly WG, Soloway B, Volberding PA. HIV expertise: a roundtable. AIDS Clin Care. 2001 Sep; 13(9):79-81, 84-5. View on Pubmed
  80. Gerbert B, Moe JC, Saag MS, Benson CA, Jacobsen DM, Feraios A, Hill ME, Bronstone A, Caspers N, Volberding PA. Toward a definition of HIV expertise: a survey of experienced HIV physicians. AIDS Patient Care STDS. 2001 Jun; 15(6):321-30. View on Pubmed
  81. Volberding P, Lange J. International perspectives on antiretroviral resistance. Introduction. J Acquir Immune Defic Syndr. 2001 Mar 01; 26 Suppl 1:S1-2. View on Pubmed
  82. Volberding P. Consensus statement: anemia in HIV infection--current trends, treatment options, and practice strategies. Anemia in HIV Working Group. Clin Ther. 2000 Sep; 22(9):1004-1020; discussion 1003. View on Pubmed
  83. Volberding P. Looking behind: time for anal cancer screening. Am J Med. 2000 Jun 01; 108(8):674-5. View on Pubmed
  84. Volberding P. When and where to start: guidelines for the initiation of antiretroviral therapy. AIDS Read. 2000 Mar; 10(3):150-5; discussion 171-4. View on Pubmed
  85. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000 Jan 19; 283(3):381-90. View on Pubmed
  86. Roberts KJ, Volberding P. Adherence communication: a qualitative analysis of physician-patient dialogue. AIDS. 1999 Sep 10; 13(13):1771-8. View on Pubmed
  87. Volberding PA. Advances in the medical management of patients with HIV-1 infection: an overview. AIDS. 1999 Sep; 13 Suppl 1:S1-9. View on Pubmed
  88. Gerbert B, Herzig K, Volberding P, Stansell J. Perceptions of health care professionals and patients about the risk of HIV transmission through oral sex: a qualitative study. Patient Educ Couns. 1999 Sep; 38(1):49-60. View on Pubmed
  89. Gerbert B, Brown B, Volberding P, Cooke M, Caspers N, Love C, Bronstone A. Physicians' transmission prevention assessment and counseling practices with their HIV positive patients. AIDS Educ Prev. 1999 Aug; 11(4):307-20. View on Pubmed
  90. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999 Jun; 179(6):1375-81. View on Pubmed
  91. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998 Jul 01; 280(1):78-86. View on Pubmed
  92. Volberding PA, Deeks SG. Antiretroviral therapy for HIV infection: promises and problems. JAMA. 1998 May 06; 279(17):1343-4. View on Pubmed
  93. Volberding PA. An aggressive approach to HIV antiretroviral therapy. Hosp Pract (1995). 1998 Jan 15; 33(1):81-4, 87-90, 95-6 passim. View on Pubmed
  94. Volberding PA. HIV/AIDS. Protease inhibitors vindicated. Lancet. 1997 Dec 20-27; 350 Suppl 3:SIII10. View on Pubmed
  95. Gerbert B, Herzig K, Volberding P. Counseling patients about HIV risk from oral sex. J Gen Intern Med. 1997 Nov; 12(11):698-704. View on Pubmed
  96. Ioannidis JP, Bassett R, Hughes MD, Volberding PA, Sacks HS, Lau J. Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 01; 16(1):22-30. View on Pubmed
  97. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997 Jun 25; 277(24):1962-9. View on Pubmed
  98. Deeks SG, Volberding PA. HIV-1 protease inhibitors. AIDS Clin Rev. 1997-1998; 145-85. View on Pubmed
  99. Volberding PA. Medicine and HIV. Interview by David Frankel. Lancet. 1996 Oct 12; 348(9033):1007-8. View on Pubmed
  100. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Sáag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996 Jul 10; 276(2):146-54. View on Pubmed
  101. Volberding PA. Age as a predictor of progression in HIV infection. Lancet. 1996 Jun 08; 347(9015):1569-70. View on Pubmed
  102. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. HIV viral load markers in clinical practice. Nat Med. 1996 Jun; 2(6):625-9. View on Pubmed
  103. Volberding PA. Improving the outcomes of care for patients with human immunodeficiency virus infection. N Engl J Med. 1996 Mar 14; 334(11):729-31. View on Pubmed
  104. Volberding PA. HIV quantification: clinical applications. Lancet. 1996 Jan 13; 347(8994):71-3. View on Pubmed
  105. Volberding PA. Controversies in initiating anti-retroviral therapy and in the use of combination therapies. Adv Exp Med Biol. 1996; 394:333-43. View on Pubmed
  106. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996 Jan; 36(1):55-63. View on Pubmed
  107. Jacobson MA, Gundacker H, Hughes M, Fischl M, Volberding P. Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 01; 11(1):45-52. View on Pubmed
  108. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, Fischl MA, Collier AC, Phair JP, Hirsch MS. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med. 1995 Aug 17; 333(7):401-7. View on Pubmed
  109. Deeks S, Volberding P. An approach to antiretroviral treatment of HIV disease. Combined antiretroviral therapy: the emerging role. Hosp Pract (1995). 1995 Aug; 30 Suppl 1:23-31. View on Pubmed
  110. Kaplan LD, Shiramizu B, Herndier B, Hahn J, Meeker TC, Ng V, Volberding PA, McGrath MS. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome. Blood. 1995 Apr 01; 85(7):1727-35. View on Pubmed
  111. Volberding P. The need for additional options in the treatment of human immunodeficiency virus infection. J Infect Dis. 1995 Mar; 171 Suppl 2:S150-4. View on Pubmed
  112. Volberding P. The value of the CD4+ count of 500 cells/microliters. Drugs. 1995; 49 Suppl 1:4-8; discussion 38-40. View on Pubmed
  113. Fogelman I, Lim L, Bassett R, Volberding P, Fischl MA, Stanley K, Cotton DJ. Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. AIDS Clinical Trials Group (ACTG). J Acquir Immune Defic Syndr (1988). 1994 Oct; 7(10):1057-63. View on Pubmed
  114. Little JW, Melnick SL, Rhame FS, Balfour HH, Decher L, Rhodus NL, Merry JW, Walker PO, Miller CE, Volberding P. Prevalence of oral lesions in symptomatic and asymptomatic HIV patients. Gen Dent. 1994 Sep-Oct; 42(5):446-50. View on Pubmed
  115. Hardy LM, Haynes BF, Volberding PA. From the Institute of Medicine. JAMA. 1994 Aug 10; 272(6):423. View on Pubmed
  116. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Phair JP, Mitsuyasu RT. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994 Aug 10; 272(6):437-42. View on Pubmed
  117. Macher A, Goosby E, Barker L, Volberding P, Goldschmidt R, Balano KB, Williams A, Hoenig L, Gould B, Daniels E. Educating primary care providers about HIV disease: multidisciplinary interactive mechanisms. Public Health Rep. 1994 May-Jun; 109(3):305-10. View on Pubmed
  118. Volberding PA. Intermittent therapy. J Acquir Immune Defic Syndr (1988). 1994 May; 7(5):454-6. View on Pubmed
  119. Volberding PA. Treatment dilemmas in HIV infection. Hosp Pract (Off Ed). 1994 Apr 15; 29(4):49-54, 59-60. View on Pubmed
  120. DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH, Rasheed S, Hollinger FB, Fischl MA, Volberding P. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. J Infect Dis. 1994 Apr; 169(4):713-21. View on Pubmed
  121. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, Testa MA. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med. 1994 Mar 17; 330(11):738-43. View on Pubmed
  122. Volberding PA. HIV, HTLV-I, and CD4+ lymphocytes. Troubles in the relationship. JAMA. 1994 Feb 02; 271(5):392-3. View on Pubmed
  123. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis. 1994 Jan; 169(1):28-36. View on Pubmed
  124. Sale M, Sheiner LB, Volberding P, Blaschke TF. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther. 1993 Nov; 54(5):556-66. View on Pubmed
  125. Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG, Henrard DR, Weller S, Corey L. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993 Oct 15; 119(8):786-93. View on Pubmed
  126. Choi S, Lagakos SW, Schooley RT, Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993 May 01; 118(9):674-80. View on Pubmed
  127. Fischl MA, Krown SE, O'Boyle KP, Mitsuyasu R, Miles S, Wernz JC, Volberding PA, Kahn J, Groopman JE, Feinberg J. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr (1988). 1993 Mar; 6(3):259-64. View on Pubmed
  128. Koch MA, Volberding PA, Lagakos SW, Booth DK, Pettinelli C, Myers MW. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group. Arch Intern Med. 1992 Nov; 152(11):2286-92. View on Pubmed
  129. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med. 1992 Aug 27; 327(9):581-7. View on Pubmed
  130. Kahn JO, Stites DP, Scillian J, Murcar N, Stryker R, Volberding PA, Naylor PH, Goldstein AL, Sarin PS, Simmon VF. A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects. AIDS Res Hum Retroviruses. 1992 Aug; 8(8):1321-5. View on Pubmed
  131. Volberding P. Optimal time to initiate anti-HIV therapy: clinical decisions without definitive data. Infect Agents Dis. 1992 Jun; 1(3):163-6. View on Pubmed
  132. Volberding PA. Epidemiology and the human immunodeficiency virus. Clinical effects of intravenous drug misuse. JAMA. 1992 Mar 25; 267(12):1666-7. View on Pubmed
  133. Gorter R, Seefried M, Volberding P. Dronabinol effects on weight in patients with HIV infection. AIDS. 1992 Jan; 6(1):127. View on Pubmed
  134. Safrin S, Volberding P. Management of the complications of human immunodeficiency virus infection. Adv Intern Med. 1992; 37:133-52. View on Pubmed
  135. Gatti G, Kahn JO, Lifson J, Williams R, Turin L, Volberding PA, Gambertoglio JG. Pharmacokinetics of GLQ223 in rats, monkeys, and patients with AIDS or AIDS-related complex. Antimicrob Agents Chemother. 1991 Dec; 35(12):2531-7. View on Pubmed
  136. Hodges TL, Kahn JO, Kaplan LD, Groopman JE, Volberding PA, Amman AJ, Arri CJ, Bouvier LM, Mordenti J, Izu AE. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrob Agents Chemother. 1991 Dec; 35(12):2580-6. View on Pubmed
  137. Lagakos S, Fischl MA, Stein DS, Lim L, Volberding P. Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. JAMA. 1991 Nov 20; 266(19):2709-12. View on Pubmed
  138. Kahn J, Northfelt D, Volberding P. Chemotherapy for AIDS-associated Kaposi's sarcoma. Oncology (Williston Park). 1991 Oct; 5(10):57-63; discussion 64, 67. View on Pubmed
  139. Drinkard CR, Decher L, Little JW, Rhame FS, Balfour HH, Rhodus NL, Merry JW, Walker PO, Miller CE, Volberding PA. Periodontal status of individuals in early stages of human immunodeficiency virus infection. Community Dent Oral Epidemiol. 1991 Oct; 19(5):281-5. View on Pubmed
  140. Volberding P. The management of early human immunodeficiency virus infection. J Thorac Imaging. 1991 Sep; 6(4):6-11. View on Pubmed
  141. Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, Volberding PA. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol. 1991 Jun; 9(6):929-40. View on Pubmed
  142. Krogstad DJ, Eveland MR, Lim LL, Volberding PA, Sadler BM. Drug level monitoring in a double-blind multicenter trial: false-positive zidovudine measurements in AIDS clinical trials group protocol 019. Antimicrob Agents Chemother. 1991 Jun; 35(6):1160-4. View on Pubmed
  143. Northfelt DW, Kahn JO, Volberding PA. Treatment of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin North Am. 1991 Apr; 5(2):297-310. View on Pubmed
  144. Evans LM, Itri LM, Campion M, Wyler-Plaut R, Krown SE, Groopman JE, Goldsweig H, Volberding PA, West SB, Mitsuyasu RT. Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Immunother (1991). 1991 Feb; 10(1):39-50. View on Pubmed
  145. Cooke M, Libman H, Smith MD, Cooney TG, Hollander H, Makadon HJ, Volberding PA. Controversies in the management of HIV-related illnesses. J Gen Intern Med. 1991 Jan-Feb; 6(1 Suppl):S46-55. View on Pubmed
  146. Tappero JW, Berger TG, Kaplan LD, Volberding PA, Kahn JO. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr (1988). 1991; 4(9):839-46. View on Pubmed
  147. Hendrix CW, Volberding PA, Chaisson RE. HIV antigen variability in ARC/AIDS. J Acquir Immune Defic Syndr (1988). 1991; 4(9):847-50. View on Pubmed
  148. Melnick SL, Hannan P, Decher L, Little JW, Rhame FS, Balfour HH, Volberding P. Increasing CD8+ T lymphocytes predict subsequent development of intraoral lesions among individuals in the early stages of infection by the human immunodeficiency virus. J Acquir Immune Defic Syndr (1988). 1991; 4(12):1199-207. View on Pubmed
  149. Volberding PA. Recent advances in the medical management of early HIV disease. J Gen Intern Med. 1991 Jan-Feb; 6(1 Suppl):S7-12. View on Pubmed
  150. Kahn JO, Kaplan LD, Gambertoglio JG, Bredesen D, Arri CJ, Turin L, Kibort T, Williams RL, Lifson JD, Volberding PA. The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study. AIDS. 1990 Dec; 4(12):1197-204. View on Pubmed
  151. Leoung GS, Feigal DW, Montgomery AB, Corkery K, Wardlaw L, Adams M, Busch D, Gordon S, Jacobson MA, Volberding PA. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med. 1990 Sep 20; 323(12):769-75. View on Pubmed
  152. Montgomery H, Adam A, Dollery CT, Weber J, Volberding P, Griffin B, Scaravilli F. Cerebral mass lesions in patients with AIDS. BMJ. 1990 Jul 28; 301(6745):226-8. View on Pubmed
  153. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 05; 322(14):941-9. View on Pubmed
  154. Jacobson MA, Peiperl L, Volberding PA, Porteous D, Toy PT, Feigal D. Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome. Transfusion. 1990 Feb; 30(2):133-7. View on Pubmed
  155. Tirelli U, Micheluz S, Franceschi S, Serraino D, Lazzarin A, Sacco OL, Clumeck N, Volberding P. Attitudes and opinions toward HIV infection of 1,008 participants to the Vth International Conference on AIDS Montreal, 4-9 June 1989. J Acquir Immune Defic Syndr (1988). 1990; 3(7):742. View on Pubmed
  156. Volberding PA. Rationale for variations in clinical trial design in different HIV disease stages. J Acquir Immune Defic Syndr (1988). 1990; 3 Suppl 2:S40-4. View on Pubmed
  157. Volberding PA, McCutchan JA. The HIV epidemic: medical and social challenges. Biochim Biophys Acta. 1989 Dec 27; 989(3):227-36. View on Pubmed
  158. Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL, Groopman JE, Volberding PA, Schooley RT. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989 Nov 03; 262(17):2405-10. View on Pubmed
  159. Volberding PA. Moving towards a uniform staging for human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1989 Sep; 7(9):1184-5. View on Pubmed
  160. Jacobson MA, Abrams DI, Volberding PA, Bacchetti P, Wilber J, Chaisson RE, Crowe S, Howard W, Moss A. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. J Infect Dis. 1989 Jun; 159(6):1029-36. View on Pubmed
  161. Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, Ziegler J, Volberding PA. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA. 1989 Feb 03; 261(5):719-24. View on Pubmed
  162. Volberding P. Supporting the health care team in caring for patients with AIDS. JAMA. 1989 Feb 03; 261(5):747-8. View on Pubmed
  163. Kaplan LD, Abrams DI, Sherwin SA, Kahn J, Volberding PA. A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex. Biotechnol Ther. 1989-1990; 1(3):229-36. View on Pubmed
  164. Volberding P. HIV infection as a disease: the medical indications for early diagnosis. J Acquir Immune Defic Syndr (1988). 1989; 2(5):421-5. View on Pubmed
  165. Kahn JO, Kaplan LD, Volberding PA, Ziegler JL, Crowe S, Saks SR, Abrams DI. Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi's sarcoma: a randomized, double-blind trial. J Acquir Immune Defic Syndr (1988). 1989; 2(3):217-23. View on Pubmed
  166. Volberding PA. Kaposi's sarcoma in AIDS. Immunol Ser. 1989; 44:345-58. View on Pubmed
  167. Volberding PA, Kaplan LD. Treatment of AIDS and its attendant malignancies. Prog Clin Biol Res. 1989; 288:459-70. View on Pubmed
  168. Wong RJ, Volberding PA. Providing clinical pharmacy services in an AIDS--oncology ambulatory-care clinic. Am J Hosp Pharm. 1988 Nov; 45(11):2351-4. View on Pubmed
  169. Chaisson RE, Leuther MD, Allain JP, Nusinoff-Lehrman S, Boone GS, Feigal D, Volberding P. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial. Arch Intern Med. 1988 Oct; 148(10):2151-3. View on Pubmed
  170. Jacobson MA, de Miranda P, Gordon SM, Blum MR, Volberding P, Mills J. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. J Infect Dis. 1988 Aug; 158(2):489-90. View on Pubmed
  171. Volberding P. Zidovudine (AZT): costs and benefits. Br J Hosp Med. 1988 Aug; 40(2):101. View on Pubmed
  172. Volberding PA. Caring for the patient with AIDS. An integrated approach. Infect Dis Clin North Am. 1988 Jun; 2(2):543-50. View on Pubmed
  173. Bottles K, McPhaul LW, Volberding P. Fine-needle aspiration biopsy of patients with acquired immunodeficiency syndrome (AIDS): experience in an outpatient clinic. Ann Intern Med. 1988 Jan; 108(1):42-5. View on Pubmed
  174. Kaplan LD, Hopewell PC, Jaffe H, Goodman PC, Bottles K, Volberding PA. Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr (1988). 1988; 1(1):23-30. View on Pubmed
  175. Volberding P. Treatment of malignant disease in AIDS patients. AIDS. 1988; 2 Suppl 1:S169-75. View on Pubmed
  176. Ammann AJ, Palladino MA, Volberding P, Abrams D, Martin NL, Conant M. Tumor necrosis factors alpha and beta in acquired immunodeficiency syndrome (AIDS) and aids-related complex. J Clin Immunol. 1987 Nov; 7(6):481-5. View on Pubmed
  177. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, Rios A, Groopman JE, Gill P, Volberding PA, Poiesz BJ. Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group. JAMA. 1987 Sep 11; 258(10):1347-51. View on Pubmed
  178. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23; 317(4):185-91. View on Pubmed
  179. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23; 317(4):192-7. View on Pubmed
  180. Abrams DI, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol. 1987 Jun; 14(2 Suppl 2):43-7. View on Pubmed
  181. Volberding PA. The role of chemotherapy for epidemic Kaposi's sarcoma. Semin Oncol. 1987 Jun; 14(2 Suppl 3):23-6. View on Pubmed
  182. Kaplan LD, Wolfe PR, Volberding PA, Feorino P, Levy JA, Abrams DI, Kiprov D, Wong R, Kaufman L, Gottlieb MS. Lack of response to suramin in patients with AIDS and AIDS-related complex. Am J Med. 1987 Mar 23; 82(3 Spec No):615-20. View on Pubmed
  183. Kaplan LD, Wofsy CB, Volberding PA. Treatment of patients with acquired immunodeficiency syndrome and associated manifestations. JAMA. 1987 Mar 13; 257(10):1367-74. View on Pubmed
  184. Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A). Cancer. 1987 Feb 01; 59(3 Suppl):620-5. View on Pubmed
  185. Hardell L, Moss A, Osmond D, Volberding P. Exposure to hair dyes and polychlorinated dibenzo-p-dioxins in AIDS patients with Kaposi sarcoma: an epidemiological investigation. Cancer Detect Prev Suppl. 1987; 1:567-70. View on Pubmed
  186. Volberding P, Moody DJ, Beardslee D, Bradley EC, Wofsy CB. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses. 1987; 3(2):115-24. View on Pubmed
  187. Chaisson RE, Allain JP, Leuther M, Volberding PA. Significant changes in HIV antigen level in the serum of patients treated with azidothymidine. N Engl J Med. 1986 Dec 18; 315(25):1610-1. View on Pubmed
  188. Abrams DI, Kaplan LD, McGrath MS, Volberding PA. AIDS-related benign lymphadenopathy and malignant lymphoma: clinical aspects and virologic interactions. AIDS Res. 1986 Dec; 2 Suppl 1:S131-40. View on Pubmed
  189. Wachter RM, Luce JM, Turner J, Volberding P, Hopewell PC. Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis. 1986 Nov; 134(5):891-6. View on Pubmed
  190. Abrams DI, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol. 1986 Sep; 13(3 Suppl 2):43-7. View on Pubmed
  191. Kaplan L, Abrams D, Volberding P. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep. 1986 Sep; 70(9):1121-2. View on Pubmed
  192. Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld W, Hadley WK, Ingram-Drake L, Volberding PA, Hopewell PC. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986 Jul; 105(1):37-44. View on Pubmed
  193. Volberding PA. Kaposi's sarcoma and the acquired immunodeficiency syndrome. Med Clin North Am. 1986 May; 70(3):665-75. View on Pubmed
  194. Abrams DI, Dilley JW, Maxey LM, Volberding PA. Routine care and psychosocial support of the patient with the acquired immunodeficiency syndrome. Med Clin North Am. 1986 May; 70(3):707-20. View on Pubmed
  195. Groopman JE, Chen FW, Hope JA, Andrews JM, Swift RL, Benton CV, Sullivan JL, Volberding PA, Sites DP, Landesman S. Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis. 1986 Apr; 153(4):736-42. View on Pubmed
  196. Steinbrook R, Lo B, Moulton J, Saika G, Hollander H, Volberding PA. Preferences of homosexual men with AIDS for life-sustaining treatment. N Engl J Med. 1986 Feb 13; 314(7):457-60. View on Pubmed
  197. Abrams DI, Kiprov DD, Goedert JJ, Sarngadharan MG, Gallo RC, Volberding PA. Antibodies to human T-lymphotropic virus type III and development of the acquired immunodeficiency syndrome in homosexual men presenting with immune thrombocytopenia. Ann Intern Med. 1986 Jan; 104(1):47-50. View on Pubmed
  198. Volberding PA, Mitsuyasu R. Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma. Semin Oncol. 1985 Dec; 12(4 Suppl 5):2-6. View on Pubmed
  199. Steinbrook R, Lo B, Tirpack J, Dilley JW, Volberding PA. Ethical dilemmas in caring for patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Nov; 103(5):787-90. View on Pubmed
  200. Volberding PA. The clinical spectrum of the acquired immunodeficiency syndrome: implications for comprehensive patient care. Ann Intern Med. 1985 Nov; 103(5):729-33. View on Pubmed
  201. Volberding PA, Abrams DI, Conant M, Kaslow K, Vranizan K, Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Sep; 103(3):335-8. View on Pubmed
  202. Kaplan L, Volberding PA. Failure (and danger) of mitozantrone in AIDS-related Kaposi's sarcoma. Lancet. 1985 Aug 17; 2(8451):396. View on Pubmed
  203. Volberding P, Abrams D. Clinical care and research in AIDS. Hastings Cent Rep. 1985 Aug; 15(4):suppl 16-8. View on Pubmed
  204. Kaminsky LS, McHugh T, Stites D, Volberding P, Henle G, Henle W, Levy JA. High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A. 1985 Aug; 82(16):5535-9. View on Pubmed
  205. Shannon K, Cowan MJ, Ball E, Abrams D, Volberding P, Ammann AJ. Impaired mononuclear-cell proliferation in patients with the acquired immune deficiency syndrome results from abnormalities of both T lymphocytes and adherent mononuclear cells. J Clin Immunol. 1985 Jul; 5(4):239-45. View on Pubmed
  206. Moss AR, Bacchetti P, Osmond D, Dritz S, Abrams D, Conant M, Volberding P, Ziegler J. Incidence of the acquired immunodeficiency syndrome in San Francisco, 1980-1983. J Infect Dis. 1985 Jul; 152(1):152-61. View on Pubmed
  207. Roth RI, Owen RL, Keren DF, Volberding PA. Intestinal infection with Mycobacterium avium in acquired immune deficiency syndrome (AIDS). Histological and clinical comparison with Whipple's disease. Dig Dis Sci. 1985 May; 30(5):497-504. View on Pubmed
  208. Dilley JW, Ochitill HN, Perl M, Volberding PA. Findings in psychiatric consultations with patients with acquired immune deficiency syndrome. Am J Psychiatry. 1985 Jan; 142(1):82-6. View on Pubmed
  209. Lie-Injo LE, Volberding P, Golden JA, Herrera AR. Hepatitis B virus (HBV) DNA in leucocytes in acquired immune deficiency syndrome (AIDS). Cytobios. 1985; 44(176):119-28. View on Pubmed
  210. Moss AR, Abrams D, Conant M, Volberding P. Incidence of the acquired immunodeficiency syndrome in San Francisco. Front Radiat Ther Oncol. 1985; 19:14-20. View on Pubmed
  211. Volberding PA, Wofsy CB, Abrams DI. Interferon and interleukin-2 therapy of Kaposi's sarcoma. Adv Exp Med Biol. 1985; 187:151-7. View on Pubmed
  212. Abrams DI, Kiprov DD, Volberding PA. Isolated thrombocytopenia in homosexual men--longitudinal follow-up. Adv Exp Med Biol. 1985; 187:117-22. View on Pubmed
  213. Abrams DI, Mess T, Volberding PA. Lymphadenopathy: end-point prodrome? Update of a 36-month prospective study. Adv Exp Med Biol. 1985; 187:73-84. View on Pubmed
  214. Volberding PA. The problem of Kaposi's sarcoma in AIDS. Front Radiat Ther Oncol. 1985; 19:91-8. View on Pubmed
  215. Moss AR, McCallum G, Volberding PA, Bacchetti P, Dritz S. Mortality associated with mode of presentation in the acquired immune deficiency syndrome. J Natl Cancer Inst. 1984 Dec; 73(6):1281-4. View on Pubmed
  216. Torti FM, Porzig KJ, Gandara DR, Volberding P, Mitchell E, Meyers FJ, Kohler M, Gribble M. Phase II trial of 4'-epi-doxorubicin in metastatic melanoma. Cancer Treat Rep. 1984 Dec; 68(12):1509-10. View on Pubmed
  217. Hammock BD, Loury DN, Moody DE, Ruebner B, Baselt R, Milam KM, Volberding P, Ketterman A, Talcott R. A methodology for the analysis of the preneoplastic antigen. Carcinogenesis. 1984 Nov; 5(11):1467-73. View on Pubmed
  218. Ziegler JL, Volberding PA, Itri LM. Failure of isotretinoin in Kaposi's sarcoma. Lancet. 1984 Sep 15; 2(8403):641. View on Pubmed
  219. Ziegler JL, Beckstead JA, Volberding PA, Abrams DI, Levine AM, Lukes RJ, Gill PS, Burkes RL, Meyer PR, Metroka CE. Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med. 1984 Aug 30; 311(9):565-70. View on Pubmed
  220. Ammann AJ, Schiffman G, Abrams D, Volberding P, Ziegler J, Conant M. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA. 1984 Mar 16; 251(11):1447-9. View on Pubmed
  221. Volberding P. Therapy of Kaposi's sarcoma in AIDS. Semin Oncol. 1984 Mar; 11(1):60-7. View on Pubmed
  222. Moon KL, Federle MP, Abrams DI, Volberding P, Lewis BJ. Kaposi sarcoma and lymphadenopathy syndrome: limitations of abdominal CT in acquired immunodeficiency syndrome. Radiology. 1984 Feb; 150(2):479-83. View on Pubmed
  223. Volberding P, Valero R, Rothman J, Gee G. Alpha interferon therapy of Kaposi's sarcoma in AIDS. Ann N Y Acad Sci. 1984; 437:439-46. View on Pubmed
  224. Abrams DI, Chinn EK, Lewis BJ, Volberding PA, Conant MA, Townsend RM. Hematologic manifestations in homosexual men with Kaposi's sarcoma. Am J Clin Pathol. 1984 Jan; 81(1):13-8. View on Pubmed
  225. Ziegler JL, Bragg K, Abrams D, Beckstead J, Cogan M, Volberding P, Baer D, Wilkinson L, Rosenbaum E, Grant K. High-grade non-Hodgkin's lymphoma in patients with AIDS. Ann N Y Acad Sci. 1984; 437:412-9. View on Pubmed
  226. Abrams DI, Lewis BJ, Volberding PA. Lymphadenopathy: endpoint or prodrome? Update of a 24-month prospective study. Ann N Y Acad Sci. 1984; 437:207-15. View on Pubmed
  227. Groopman JE, Volberding PA. The AIDS epidemic: continental drift. Nature. 1984 Jan 19-25; 307(5948):211-2. View on Pubmed
  228. Lozada F, Silverman S, Migliorati CA, Conant MA, Volberding PA. Oral manifestations of tumor and opportunistic infections in the acquired immunodeficiency syndrome (AIDS): findings in 53 homosexual men with Kaposi's sarcoma. Oral Surg Oral Med Oral Pathol. 1983 Nov; 56(5):491-4. View on Pubmed
  229. Rubenstein SA, Jenkin WM, Conant MA, Volberding PA. Disseminated Kaposi's sarcoma in male homosexuals. J Am Podiatry Assoc. 1983 Aug; 73(8):413-7. View on Pubmed
  230. Mitsuyasu R, Groopman J, Volberding P. Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma. N Engl J Med. 1983 Jun 23; 308(25):1535-6. View on Pubmed
  231. Ammann AJ, Abrams D, Conant M, Chudwin D, Cowan M, Volberding P, Lewis B, Casavant C. Acquired immune dysfunction in homosexual men: immunologic profiles. Clin Immunol Immunopathol. 1983 Jun; 27(3):315-25. View on Pubmed
  232. Moss AR, Bacchetti P, Gorman M, Dritz S, Conant M, Abrams DI, Volberding P, Ziegler J. AIDS in the "gay" areas of San Francisco. Lancet. 1983 Apr 23; 1(8330):923-4. View on Pubmed
  233. Volberding P, Conant MA, Stricker RB, Lewis BJ. Chemotherapy in advanced Kaposi's sarcoma. Implications for current cases in homosexual men. Am J Med. 1983 Apr; 74(4):652-6. View on Pubmed
  234. Drew WL, Conant MA, Miner RC, Huang ES, Ziegler JL, Groundwater JR, Gullett JH, Volberding P, Abrams DI, Mintz L. Cytomegalovirus and Kaposi's sarcoma in young homosexual men. Lancet. 1982 Jul 17; 2(8290):125-7. View on Pubmed
  235. Conant MA, Volberding P, Fletcher V, Lozada FI, Silverman S. Squamous cell carcinoma in sexual partner of Kaposi sarcoma patient. Lancet. 1982 Jan 30; 1(8266):286. View on Pubmed
  236. Volberding PA, Friedman MA, Resser KJ, Phillips TL. Therapy of liver tumors metastatic from colorectal cancer with whole-liver radiation combined with 5-FU, adriamycin, and methotrexate. Cancer Chemother Pharmacol. 1982; 9(1):17-21. View on Pubmed
  237. Fischbach M, Volberding P, Talal N, Levy J. Genetic analysis of induction of anti-polyadenylic acid antibodies and xenotropic type-C viruses. Clin Exp Immunol. 1981 Jun; 44(3):615-9. View on Pubmed
  238. Friedman MA, Volberding PA, Cassidy MJ, Resser KJ, Wasserman TH, Phillips TL. Therapy of hepatocellular cancer with combined intrahepatic arterial chemotherapy and whole liver irradiation. Ann Acad Med Singapore. 1980 Apr; 9(2):260-3. View on Pubmed
  239. Friedman MA, Volberding PA, Cassidy MJ, Resser KJ, Wasserman TH, Phillips TL. Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: a Northern California Oncology Group Study. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1885-8. View on Pubmed
  240. Moldow CF, Volberding P, McGrath M, Lee JL. Avian tumour virus interactions with chicken fibroblast membranes: partial characterization of initial attachment site activity. J Gen Virol. 1977 Nov; 37(2):385-98. View on Pubmed